Sec Form 4 Filing - Silva Francisco @ BioRestorative Therapies, Inc. - 2022-11-21

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Silva Francisco
2. Issuer Name and Ticker or Trading Symbol
BioRestorative Therapies, Inc. [ BRTX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
VP of Research and Development
(Last) (First) (Middle)
40 MARCUS DRIVE
3. Date of Earliest Transaction (MM/DD/YY)
11/21/2022
(Street)
MELVILLE, NY11747
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2022 P 943 A $ 2.6162 166,046( 1 ) D
Common Stock 12,136 I IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $ 3,000 ( 2 ) 12/07/2022 Common Stock 1 1 D
Stock Option $ 3,000 ( 2 ) 10/04/2023 Common Stock 1 1 D
Stock Option $ 3,000 ( 2 ) 02/18/2024 Common Stock 3 3 D
Stock Option $ 3,000 03/12/2014 03/11/2024 Common Stock 1 1 D
Stock Option $ 3,000 ( 2 ) 10/23/2024 Common Stock 9 9 D
Stock Option $ 3,000 ( 2 ) 09/04/2025 Common Stock 6 6 D
Stock Option $ 3,000 ( 2 ) 06/10/2026 Common Stock 15 15 D
Stock Option $ 3,000 ( 2 ) 07/12/2027 Common Stock 20 20 D
Stock Option $ 3,000 ( 2 ) 10/29/2028 Common Stock 25 25 D
Stock Option $ 5.08 ( 3 ) 03/18/2031 Common Stock 293,479 293,479 D
Stock Option $ 5.08 ( 4 ) 11/04/2031 Common Stock 42,059 42,059 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Silva Francisco
40 MARCUS DRIVE
MELVILLE, NY11747
X VP of Research and Development
Signatures
/s/ Francisco Silva 11/21/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
( 2 )The option is currently exercisable.
( 3 )The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
( 4 )The option vests and becomes exe rcisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.